Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Dafydd A Dart, Maqsood S Mansoor, Paul M Loadman & Steven M Picksley. (2001) Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein. Expert Opinion on Therapeutic Patents 11:12, pages 1825-1835.
Read now
Read now
Articles from other publishers (18)
K.A. Becker & D.J. Jerry. 2015. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Ehsan Sarafraz-YazdiWilbur B. BowneVictor AdlerKelley A. SookrajVernon Wu, Vadim Shteyler, Hunaiz Patel, William Oxbury, Paul Brandt-Rauf, Michael E. ZenilmanJosef Michl & Matthew R. Pincus. (2010) Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences 107:5, pages 1918-1923.
Crossref
Crossref
Wilbur B. Bowne, Kelley A. Sookraj, Michael Vishnevetsky, Victor Adler, Ehsan Sarafraz-Yazdi, Sunming Lou, Jesco Koenke, Vadim Shteyler, Kamran Ikram, Michael Harding, Martin H. Bluth, Mou Ng, Paul W. Brandt-Rauf, Raqibul Hannan, Stephan Bradu, Michael E. Zenilman, Josef Michl & Matthew R. Pincus. (2008) The Penetratin Sequence in the Anticancer PNC-28 Peptide Causes Tumor Cell Necrosis Rather Than Apoptosis of Human Pancreatic Cancer Cells. Annals of Surgical Oncology 15:12, pages 3588-3600.
Crossref
Crossref
Maike Sieben, Kerstin Herzer, Maja Zeidler, Vera Heinrichs, Barbara Leuchs, Martin Schuler, Jan J Cornelis, Peter R Galle, Jean Rommelaere & Markus Moehler. (2008) Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World Journal of Gastroenterology 14:24, pages 3819.
Crossref
Crossref
Kevin L. Lorick, Yien‐Che Tsai, Yili Yang & Allan M. Weissman. 2007. Protein Degradation Series. Protein Degradation Series
44
101
.
Josef Michl, Bruce Scharf, Anna Schmidt, Chan Huynh, Raquibul Hannan, Hans von Gizycki, Fred K Friedman, Paul Brandt-Rauf, Robert L. Fine & Matthew R. Pincus. (2006) PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growthin vivo. International Journal of Cancer 119:7, pages 1577-1585.
Crossref
Crossref
E Claire Dees & Robert Z Orlowski. (2006) Targeting the ubiquitin–proteasome pathway in breast cancer therapy. Future Oncology 2:1, pages 121-135.
Crossref
Crossref
Ratchada Cressey, Sarunya Pimpa, Waragorn Tontrong, Onusa Watananupong & Nirush Leartprasertsuke. (2006) Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Letters 233:2, pages 232-239.
Crossref
Crossref
Katerina V. Gurova, Jason E. Hill, Olga V. Razorenova, Peter M. Chumakov & Andrei V. Gudkov. (2004) p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism. Cancer Research 64:6, pages 1951-1958.
Crossref
Crossref
Jianhua Zhao, Mijuan Wang, Jie Chen, Aiping Luo, Xiuqin Wang, Min Wu, Dali Yin & Zhihua Liu. (2002) The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53–HDM2 complex structure. Cancer Letters 183:1, pages 69-77.
Crossref
Crossref
K. W. Hunter & R. W. Williams. (2002) Complexities of Cancer Research: Mouse Genetic Models. ILAR Journal 43:2, pages 80-88.
Crossref
Crossref
D. Joseph Jerry & Michelle A. Ozbun. 2002. Encyclopedia of Cancer. Encyclopedia of Cancer
415
431
.
Gitali Ganguli, Joseph Abecassis & Bohdan Wasylyk. (2000) MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. The EMBO Journal 19:19, pages 5135-5147.
Crossref
Crossref
Esther H Chang, Kathleen F Pirollo & Kerrie B Bouker. (2000) Tp53 gene therapy: a key to modulating resistance to anticancer therapies?. Molecular Medicine Today 6:9, pages 358-365.
Crossref
Crossref
Ranju Ralhan, Agarwal Sandhya, Mathur Meera, Wasylyk Bohdan & Shukla K. Nootan. (2000) Induction of MDM2-P2 Transcripts Correlates with Stabilized Wild-Type p53 in Betel- and Tobacco-Related Human Oral Cancer. The American Journal of Pathology 157:2, pages 587-596.
Crossref
Crossref
Christine Wasylyk, Roberto Salvi, Manuela Argentini, Christine Dureuil, Isabelle Delumeau, Joseph Abecassis, Laurent Debussche & Bohdan Wasylyk. (1999) p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18:11, pages 1921-1934.
Crossref
Crossref
K. Roemer. (1999) Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators. Biological Chemistry 380:7-8.
Crossref
Crossref
Deborah A. Freedman, Charles B. Epstein, Judith C. Roth & Arnold J. Levine. (1997) A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein. Molecular Medicine 3:4, pages 248-259.
Crossref
Crossref